Cagrilintide: difference between revisions
Diff·revision 13 → 14·15:09, 23 Feb 2025
Difference between revision 13 and revision 14 of Cagrilintide. 1 line changed; the page grew by 40 bytes.
| Revision 13 — 22:44, 5 Feb 2025 INN_Ingrid (talk) rm the equipotency claim — the cited paper does not make it 3,147 bytes ±0 | Revision 14 — 15:09, 23 Feb 2025 IcodecIndra (talk) split §Pharmacology into receptor binding and downstream signalling 3,187 bytes +40 | ||
|---|---|---|---|
| 7 | | Combination = [[CagriSema]] with [[Semaglutide|semaglutide]] | 7 | | Combination = [[CagriSema]] with [[Semaglutide|semaglutide]] |
| 8 | }} | 8 | }} |
| + | 9 | {{medical|talk=Investigational status}} | |
| 9 | 10 | ||
| 10 | '''Cagrilintide''' is a long-acting analogue of [[Amylin|amylin]], engineered to resist the aggregation that makes the native human sequence undevelopable and acylated for [[Albumin binding half-life extension|albumin binding]] so that weekly dosing is possible.{{r|lau2021}} | 11 | '''Cagrilintide''' is a long-acting analogue of [[Amylin|amylin]], engineered to resist the aggregation that makes the native human sequence undevelopable and acylated for [[Albumin binding half-life extension|albumin binding]] so that weekly dosing is possible.{{r|lau2021}} |